Poklis Alphonse, Backer Ronald
Department of Pathology, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298-0165, USA.
J Anal Toxicol. 2004 Sep;28(6):422-5. doi: 10.1093/jat/28.6.422.
A study of the urinary concentration of fentanyl (F) and its major metabolite norfentanyl (NF) in chronic pain patients treated with the Duragesic continuous release transdermal patches is presented. These patches are available in 10, 20, 30, and 40 cm(2) sizes releasing 25, 50, 75, and 100 microg/h F, respectively. F is rapidly and extensively metabolized, with NF as the major metabolite. Five hundred-forty six random urine specimens were collected from chronic pain patients wearing 25, 50, 75, or 100 ug F transdermal patches. Urine specimens were collected from hours after application to several days later after continuous F release. Each specimen was analyzed for F, NF, creatinine, and pH. Additionally, each was screened by enzyme immunoassay for the following: amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone, phencyclidine, d-propoxyphene, opiates, and marijuana metabolites. All positive screening results were confirmed by gas chromatography-mass spectrometry (GC-MS). F and NF were isolated from urine by solid-phase extraction then identified and quantified by GC-MS in SIM mode. The LODs and LOQs for F and NF were 3 ng/mL, respectively. The results of F and NF analysis of urine form those wearing 25-microg patches (N = 142) was mean F, 47 ng/mL with a range of 0 to 983 ng/mL, and 97% of the specimens contained < 200 ng/mL and mean NF, 175 ng/mL with a range of 0-980 ng/mL, while 95% of the specimens contained < 400 ng/mL. The results of F and NF analysis of urine form those wearing 50 microg patches (N = 184) was: mean F, 74 ng/mL with a range of 0 to 589 ng/mL, and 92% of the specimens contained < 200 ng/mL and mean NF, 257 ng/mL with a range of 0-2200 ng/mL, and 98% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 75 microg patches (N = 85) was mean F, 107 ng/mL with a range of 0 to 1280 ng/mL, and 98% of the specimens contained < 400 ng/mL and mean NF, 328 ng/mL with a range of 0-5630 ng/mL, and 99% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 100 ug patches (N = 135) was mean F, 100 ng/mL with a range of 0 to 1080 ng/mL, while 96% of the specimens contained < 400 ng/mL and mean NF, 373 ng/mL with a range of 0-5730 ng/mL, and 95% of the specimens contained < 1000 ng/mL. The incidence of other drugs detected as a percentage the specimens was opiates, 48%, benzodiazepines, 43%; barbiturates, 3%; methadone, 4%; marijuana metabolite, 3%; and cocaine metabolite, 1%. With the exception of F and/or NF, no other drugs were detected in 25% of the specimens. These data demonstrate the wide variation in concentrations of F and NF in random urine specimens following application of Duragesic patches. However, these values obtained during therapeutic use far exceed concentrations previously reported in fatal poisoning. In general, one may expect to find urine NF concentrations 3-4 times higher than those of F.
本文介绍了一项关于使用多瑞吉持续释放透皮贴剂治疗的慢性疼痛患者尿液中芬太尼(F)及其主要代谢产物去甲芬太尼(NF)浓度的研究。这些贴剂有10、20、30和40平方厘米四种规格,分别释放25、50、75和100微克/小时的F。F能快速且广泛地代谢,NF是主要代谢产物。从佩戴25、50、75或100微克F透皮贴剂的慢性疼痛患者中收集了546份随机尿液标本。尿液标本在开始持续释放F后的数小时至数天内收集。每份标本都分析了F、NF、肌酐和pH值。此外,每份标本还通过酶免疫法进行以下筛查:苯丙胺、巴比妥类、苯二氮卓类、可卡因代谢物、美沙酮、苯环利定、右旋丙氧芬、阿片类药物和大麻代谢物。所有阳性筛查结果均通过气相色谱 - 质谱联用(GC - MS)进行确认。通过固相萃取从尿液中分离出F和NF,然后在选择离子监测(SIM)模式下用GC - MS进行鉴定和定量。F和NF的检测限(LOD)均为3纳克/毫升。佩戴25微克贴剂患者(N = 142)尿液F和NF分析结果为:F平均47纳克/毫升,范围为0至983纳克/毫升,97%的标本F含量<200纳克/毫升;NF平均175纳克/毫升,范围为0至980纳克/毫升,95%的标本NF含量<400纳克/毫升。佩戴50微克贴剂患者(N = 184)尿液F和NF分析结果为:F平均74纳克/毫升,范围为0至589纳克/毫升,92%的标本F含量<200纳克/毫升;NF平均257纳克/毫升,范围为0至2200纳克/毫升,98%的标本NF含量<1000纳克/毫升。佩戴75微克贴剂患者(N = 85)尿液F和NF分析结果为:F平均107纳克/毫升,范围为0至1280纳克/毫升,98%的标本F含量<400纳克/毫升;NF平均328纳克/毫升,范围为0至5630纳克/毫升,99%的标本NF含量<1000纳克/毫升。佩戴100微克贴剂患者(N = 135)尿液F和NF分析结果为:F平均100纳克/毫升,范围为0至1080纳克/毫升,96%的标本F含量<400纳克/毫升;NF平均373纳克/毫升,范围为0至5730纳克/毫升,95%的标本NF含量<1000纳克/毫升。检测出的其他药物在标本中所占百分比为:阿片类药物48%,苯二氮卓类43%;巴比妥类3%;美沙酮4%;大麻代谢物3%;可卡因代谢物1%。除F和/或NF外,25%的标本未检测到其他药物。这些数据表明,使用多瑞吉贴剂后随机尿液标本中F和NF浓度存在很大差异。然而,这些治疗期间获得的值远远超过先前致命中毒报告中的浓度。一般来说,尿液中NF浓度可能比F高3 - 4倍。